Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)
ID: 353382Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353382

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-190.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 3, 2024 12:00 AM
  4. 4
    Due Oct 18, 2024 12:00 AM
Description

The National Institutes of Health is offering a federal grant opportunity titled "Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)". This grant aims to support the development and validation of predictive tools and/or biomarkers that can inform individual-level treatment selection for depression. The grant will be provided in two phases, UG3 and UH3, and will involve multi-disciplinary teams addressing scientific, technical, clinical, regulatory, and commercialization requirements. In the UG3 phase, investigators are expected to identify potential tools and/or biomarkers that can predict differential response to different depression treatments. In the UH3 phase, independent clinical trials will be conducted to validate the utility of the identified tools/biomarkers. The overall goal of this grant is to test and evaluate various tools/biomarkers as predictors of response to established depression treatments. For more information and to apply, visit the following link: Precision Mental Health Grant.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-MH-25-190-Full-Announcement.html
4/10/2024
Similar Opportunities
Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH) (U01 Clinical Trial Optional)". This grant aims to encourage research using novel behavioral measures to advance precision assessment, prognosis, and treatment of mental disorders. The focus of this grant is to develop or optimize behavioral tasks that measure individual differences and demonstrate added utility for clinical prediction when combined with standard clinical diagnosis. Additionally, the grant aims to form a data infrastructure that can support computational approaches to build tools for clinical decision making. The maximum award ceiling for this grant is $2,500,000. Eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for application submission is October 18, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-195.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-195.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)". This grant aims to identify neurophysiological measures potential assays for treatment development research. The funding opportunity will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The goal of this initiative is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates. By doing so, it aims to hasten the development of more effective treatments for mental disorders. The grant does not require cost sharing or matching requirements and falls under the category of Health. The grant is a Cooperative Agreement and is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The close date for this grant opportunity is June 20, 2025, and the archive date is July 26, 2025. For more information and to apply, please visit the following link: [Novel Assays to Address Translational Gaps in Treatment Development Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-087.html). For any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)". This grant aims to support pilot research in developing and testing innovative psychosocial interventions and/or targets for mental disorders. The grant will provide up to two years of support for evaluating target engagement and establishing intervention parameters, and up to three years of support for replicating target engagement and testing the association between target engagement and clinical outcomes. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. For more information, visit the following link: [Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-21-135.html).
Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance Use and Mental Health Disorders (R01 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance Use and Mental Health Disorders (R01 Clinical Trial Required)". This grant aims to support research efforts in the field of Substance Use Disorder (SUD) and Mental Health Disorders (MHD) by investigating the effects of neuromodulation on brain circuits and behaviors related to both SUD and MHD. The research studies funded by this grant will focus on identifying inclusion/exclusion criteria that capture the variability in symptoms of both SUD and MHD. Additionally, the studies will involve measuring the engagement of circuit-level targets in response to neuromodulation and assessing cognitive and behavioral dimensions relevant to both SUD and MHD. The ultimate goal is to gain a better understanding of neurobehavioral function and develop accurate models of dysfunction shared and distinct between these conditions. This grant opportunity falls under the category of Health and is classified as a discretionary grant. The grant does not require cost sharing or matching. The closing date for applications is August 15, 2024, and the archive date is September 20, 2024. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. For more information and to apply, please visit the following link: [Additional Information](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-035.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health is offering a grant for the early stage testing of pharmacologic or device-based interventions for the treatment of mental disorders. This grant aims to support the development and testing of therapeutic interventions that evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The grant does not require cost sharing or matching. The deadline for application submission is October 15, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-21-137.html](http://grants.nih.gov/grants/guide/pa-files/PAR-21-137.html).